A Phase I, Ascending Dose Randomized, Blinded, Placebo-Controlled, Single-Center Study to evaluate the safety and tolerability of of Intravenous FDY-5301 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs FDY 5301 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; First in man
- 17 May 2017 Status changed from recruiting to completed.
- 23 Sep 2016 Status changed from not yet recruiting to recruiting, as per Faraday Pharmaceuticals media release.
- 07 Sep 2016 New trial record